ZBH Stock Chart & Stats
$1505.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1505.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,368.51 - $2,145.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$306.70B
Enterprise Value$23.68K
Total Cash (Recent Filing)$410.00M
Total Debt (Recent Filing)$7.48B
Price to Earnings (P/E)22.4
Beta0.01
Next Earnings
Nov 04, 2026EPS Estimate
31.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.13
Shares Outstanding190,737,690
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)1.40
Price to Sales (P/S)2.16
P/FCF Ratio12.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,793.90Price Target Upside19.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)144.82
Revenue Forecast (FY)$145.97B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationImproving operating and free cash flow indicates that Zimmer Biomet is converting sales and earnings into internally generated funding. This supports investment in products and commercial capabilities, strengthens financial resilience, and provides flexibility for capital returns or strategic uses.
Technology And Robotics GrowthRapid growth in technology-enabled offerings gives Zimmer Biomet an expanding business beyond traditional implants. Strong ROSA adoption and continued robotics development can deepen surgeon relationships, support differentiated solutions, and increase exposure to higher-growth procedure-enabling categories.
Steady Revenue Growth And Raised OutlookConsistent sales expansion across the business, together with raised full-year guidance, supports the durability of demand for Zimmer Biomet's orthopedic products. A stable growth profile improves planning visibility and helps fund ongoing innovation, market development, and commercial execution.
Bears Say
Margin CompressionRecent gross and operating margin declines show that investments in the U.S. commercial organization and higher manufacturing costs are weighing on profitability. If these costs persist, they could limit earnings conversion and reduce the financial benefit of otherwise steady revenue growth.
Pricing And Reimbursement PressurePricing erosion directly threatens the economics of Zimmer Biomet's implant portfolio, while reimbursement changes can increase pressure on providers and purchasing decisions. Persistent pricing headwinds would make it harder to protect margins and translate procedure growth into comparable profit growth.
Knee And China WeaknessWeak knee performance affects a core reconstructive category and highlights uneven momentum across Zimmer Biomet's geographic markets. China and emerging-market softness can prolong international pressure, weaken mix, and require additional commercial effort before these areas contribute more strongly.
Zimmer Biomet Holdings News
ZBH FAQ
What was Zimmer Biomet Holdings’s price range in the past 12 months?
Zimmer Biomet Holdings lowest stock price was $1368.51 and its highest was $2145.00 in the past 12 months.
What is Zimmer Biomet Holdings’s market cap?
Zimmer Biomet Holdings’s market cap is $306.70B.
When is Zimmer Biomet Holdings’s upcoming earnings report date?
Zimmer Biomet Holdings’s upcoming earnings report date is Nov 04, 2026 which is in 54 days.
How were Zimmer Biomet Holdings’s earnings last quarter?
Zimmer Biomet Holdings released its earnings results on Aug 05, 2026. The company reported $35.105 earnings per share for the quarter, beating the consensus estimate of $34.087 by $1.018.
Is Zimmer Biomet Holdings overvalued?
According to Wall Street analysts Zimmer Biomet Holdings’s price is currently Undervalued.
Does Zimmer Biomet Holdings pay dividends?
Zimmer Biomet Holdings does not currently pay dividends.
What is Zimmer Biomet Holdings’s EPS estimate?
Zimmer Biomet Holdings’s EPS estimate is 31.92.
How many shares outstanding does Zimmer Biomet Holdings have?
Zimmer Biomet Holdings has 190,737,690 shares outstanding.
What happened to Zimmer Biomet Holdings’s price movement after its last earnings report?
Zimmer Biomet Holdings reported an EPS of $35.105 in its last earnings report, beating expectations of $34.087. Following the earnings report the stock price went up 2.612%.
Which hedge fund is a major shareholder of Zimmer Biomet Holdings?
Currently, no hedge funds are holding shares in MX:ZBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zimmer Biomet Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,793.90 (19.20% Upside)
$1,793.90 (19.20% Upside)
Blogger Sentiment
Bullish
MX:ZBH Sentiment 71%
Sector Average 61%
Sector Average 61%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.68%
12-Months-Change
Fundamentals
Return on Equity
1.04%
Trailing 12-Months
Asset Growth
-0.29%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
ZBH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple strong operational and financial positives — revenue beat, raised guidance, robust cash generation, rapid technology and hip product adoption, successful Paragon integration and a sizable buyback — while acknowledging near-term headwinds including margin pressure from investment and manufacturing costs, pricing erosion risk, weakness in knees and China, and some supply constraints. Management framed 2026 as a transitional year with confidence that investments and go-to-market changes will improve execution and performance into 2027.View all MX:ZBH earnings summariesZBH Net sales Breakdown
40.36% Knees
25.43% Hips
26.12% S.E.T
8.09% Technology & Data, Bone Cement and Surgical
ZBH Stock 12 Month Forecast
Average Price Target
$1,793.90
▲(19.20% Upside)